Novel glucocerebrosidase activator; Non-inhibitory chaperones of glucocerebrosidase

BMS-986187 is a novel potent, positive allosteric modulator of δ-opioid receptor with EC50 of 30 nM, 100-fold selectivity over μ-opioid receptor..

Novel modulator of the UNC119-Cargo Interaction, potently and selectively inhibiting the binding of a myristoylated peptide representing the N-terminus of Src kinase to UNC119A

A potent and efficacious hERG channel activator steeply potentiates current amplitudes more than 10-fold with EC50 of 0.5 uM.

Potent and selective blocker for TMEM16A/Anoctamin-1 (ANO1)

TM5007 is a poent inhibitor plasminogen activator inhibitor-1 (PAI-1) with IC50 of 29 uM, exhibits no inhibitory activity against any of the closely related serpins or serine proteases at 250 uM. .

Novel blood brain barrier (BBB) penetrable two-photon imaging probe, labelling plaques and cerebral amyloid angiopathies (CAAs)

Potent and selective mGluR8-specific orthosteric agonist

Novel selective PAD4 inhibitor

Potent and ATP-binding site inhibitor of GSK-3

Novel potent and selective RIP3 kinase inhibitor

A non-peptide small molecule agonist of the PTH1 receptor, activates both the cAMP and calcium signaling pathways..

Novel potent agonist of HTL/KAI2, stimulating activity for Arabidopsis seed germination

DPI-201-106 is a cardioselective inhibitor of the TTX-resistant h1 Na channel inactivation. DPI-201-106 inhibits the L-type calcium current, and inward and delayed rectifier potassium currents.

Potent, orally active and S1P3-sparing S1P1 agonist

Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models

Novel VISTA (V-domain immunoglobulin suppressor of T-cell activation) agonist

NPY5RA972 is a neuropeptide Y Y5 antagonist.

Novel modulator of Hydra head regeneration, inducing a homeotic transformation in Hydra

HAT Inhibitor II is a novel p300/CBP-selective histone acetyltransferase inhibitor.Histone Acetyltransferase Inhibitor II is a potent and cell permeable p300 inhibitor, with an IC50 of 5µM; Histone Acetyltransferase Inhibitor II can be used in cancer research.

CID 2745687 is a competitive, reversible antagonist of the orphan receptor GPR35.

SGC2085 is a Potent and Selective Coactivator Associated Arginine Methyltransferase 1 (CARM1) Inhibitor with an IC50 of 50 nM and more than undred-fold selectivity over other PRMTs. CARM1 is an important positive modulator of Wnt/β-catenin transcription and neoplastic transformation in colorectal cancer as well as a critical factor in estrogen-stimulated breast cancer growth, and its depletion results in decreased proliferation of myeloid leukemia cells in vivo.

RH01687 is a small molecule that protect pancreatic β cells against endoplasmic reticulum stress-induced cell death.

LP99 is the first potent and selective BRD7/9 bromodomain inhibitor with Kd of 99 nM for BRD9.

GSK106 is a negative control compound used in binding and functional assays for PAD4 inhibitors.

B3C is an activator of transcription factor MEF2D; Enhabcer of cognitive capacity; Blocker of N-methyl-D-aspartate receptors.

DCN10809, also known as Paclitaxel succinate NHS ester, is a paclitaxel derivative with a succinic acid linker, in which the carboxy group is activated with an NHS ester. The NHS ester group is highly reactive to amino group or hydroxy group, and can be used to conjugate with other molecules such as peptides, proteins, antibodies or enzymes, or polymers. Paclitaxel-Succinic acid is a useful agent to make Paclitaxel-conjugate for drug delivery, nanodrug research.

Azvudine (RO 0622) is a potent HCV NS5B RNA polymerase inhibitor, inhibits HCV replication in the replicon system with IC50 of 24 nM; inhibits RNA synthesis by HCV polymerases from either HCV genotypes 1a and 1b or containing S96T or S282T point mutations (IC50=10-100 nM).

MF-766 (MF766) is a highly potent and selective EP(4) antagonist with binding Ki of 0.23 nM, displays no significant affinity (>7000-fold selectivity) against other PG receptors (IC50>1500 nM); behaved as a full antagonist with an IC50 of 1.4 nM (shifted to 1.8 nM in the presence of 10% HS) in the functional assay; exhibits blockade of inhibition of TNFa-induced IP10 release by the specific EP4 agonist L-000902688 (IC50=9.5 nM); demonstrates potency and efficacy of in the rat AIA model measuring inhibition of paw swelling.

MAP4K4-IN-17 is a potent and highly selective MAP4K4 inhibitor with IC50 of 14.9 nM, showes improved overall drug-like properties compared to PF-06260933.